Check for updates

OPEN ACCESS

EDITED BY Xiaofeng Yang, Temple University, United States

REVIEWED BY Maria do Céu Gonçalves da Costa, University of Lisbon, Portugal Heyue Du, TidalHealth, United States

*CORRESPONDENCE Xingwei Di ⊠ dxwwww0929@163.com

RECEIVED 01 October 2024 ACCEPTED 08 April 2025 PUBLISHED 06 May 2025 CORRECTED 27 June 2025

CITATION

Jiang J, Zhong Q, Zhou X, Zhou L, Zheng J, Liu B and Di X (2025) Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system. Front. Cardiovasc. Med. 12:1504671. doi: 10.3389/fcvm.2025.1504671

COPYRIGHT

© 2025 Jiang, Zhong, Zhou, Zhou, Zheng, Liu and Di. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

Jiazhen Jiang¹, Qian Zhong², Xinyu Zhou¹, Lisi Zhou³, Jiyuan Zheng¹, Bingshuo Liu⁴ and Xingwei Di^{5*}

¹The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ²Department of Cardiovascular Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China, ³Clinical Medical College of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ⁴The Fifth Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ⁵Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of

Background: Amlodipine, a widely prescribed clinical medication, is associated with adverse reactions that can impede the proper execution of treatment regimens. The lack of systematic studies on amlodipine's adverse drug reactions (ADRs) necessitates further investigation to facilitate refined population management and optimize therapeutic outcomes.

Method: This study leveraged the FDA Adverse Event Reporting System (FAERS) database, extracting reports submitted exclusively by healthcare professionals where amlodipine was designated as the primary suspect (PS). Four risk signal detection methods were employed: Ratio of Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean, to conduct a comprehensive analysis of amlodipine-related ADRs. Furthermore, subgroup analyses stratified by gender and age were performed, with multivariable logistic regression utilized to validate the reliability of the findings.

Results: Across the general population, male cohort, female cohort, elderly group, and younger demographic, the four signal detection methods collectively identified 513, 348, 403, 246, and 260 potential ADRs associated with amlodipine, respectively. Intersection analysis revealed 27 common ADRs, including gingival hypertrophy, vasoplegia syndrome, and distributive shock. Subsequent multivariable logistic regression confirmed amlodipine's role as an independent risk factor for all 27 ADRs (OR > 1, P < 0.05).

Conclusion: This study provides compelling evidence that amlodipine poses risks of peripheral edema, shock, and dyspnea, among others. Additionally, it identified previously unreported ADRs such as abnormal full blood count and personality disorder. These findings underscore the importance of exercising caution when prescribing amlodipine to high-risk individuals with a history of hyperkalemia, cardiac structural abnormalities, or airway obstruction.

KEYWORDS

amlodipine, adverse drug reactions, FDA adverse event reporting system, risk signal detection, logistic regression

1 Introduction

Amlodipine, a widely prescribed dihydropyridine calcium channel blocker, has been predominantly utilized in the treatment of hypertension, coronary artery disease, and other cardiovascular ailments since its approval in 1991 (1). As a calcium channel antagonist, amlodipine exerts its therapeutic effect by inhibiting calcium ion influx into vascular smooth muscle cells, thereby inducing vasodilation and reducing peripheral vascular resistance, ultimately leading to a decrease in blood pressure (2). Among antihypertensive medications, calcium channel blockers (CCBs) are the most frequently prescribed, with amlodipine accounting for a substantial 37% of prescriptions (3), underscoring its extensive clinical application. Amlodipine's pharmacokinetic profile, characterized by low renal clearance (7 ml/min/mg), extended halflife (35-50 h), and high bioavailability (60%-80%) (4), renders it suitable for once-daily dosing, a feature highly favored by clinicians.

Notwithstanding its widespread use, an observational study revealed that amlodipine, when used as monotherapy, is associated with the highest incidence of adverse reactions among antihypertensive agents (5). The FDA label indicates that the most common adverse effects of amlodipine include edema, dizziness, flushing, and palpitations. Recent years have witnessed the emergence of additional adverse reactions, including acute kidney injury (6), thrombocytopenia (7), bradycardia (1), dermatological complications (8–10), gingival hyperplasia (11), and even shock (12). These adverse effects not only directly impact patients' quality of life and increase the likelihood of treatment discontinuation but may also pose life-threatening risks in severe cases (13), presenting significant challenges to the clinical application of amlodipine.

While reports of amlodipine-related adverse reactions are on the rise, the majority of these accounts stem from individual case reports, lacking robust supporting evidence. Moreover, accurate assessment of drug-specific adverse reactions in clinical observations is hampered by limited subject numbers and short observation periods. Consequently, signal generation based on large-scale databases has emerged as a crucial method for detecting adverse drug reactions (14). This study represents the first systematic analysis of amlodipine-related adverse reactions grounded in real-world data and employing multiple methodological approaches. The adverse reactions identified have been corroborated through four distinct methods to enhance credibility. The primary objective is to assist clinicians in recognizing potential clinical adverse reactions, thereby strengthening the monitoring and refined management of amlodipine therapy, which is paramount for optimizing treatment outcomes.

2 Materials and methods

2.1 Data source

This observational analysis utilizes the FDA Adverse Event Reporting System (FAERS) database, which is updated quarterly and comprises self-reported data from both healthcare professionals (physicians, pharmacists, healthcare specialists, and registered nurses) and non-healthcare professionals (consumers, lawyers, sales representatives, and others). The FAERS database has been extensively employed in identifying potential drug adverse reactions. It encompasses unique identification numbers, report dates, reporting countries, primary reporter qualifications, patient demographic information (such as gender, age, and weight), suspected and concomitant medications and their indications, ADR occurrence dates, and ADR manifestations.

Given amlodipine's market approval in 1991, this study extracted report files from the FAERS database (https://fis.fda.gov/extensions/ FPD-QDE-FAERS/FPD-QDE-FAERS.html) spanning from the database's inception (Q1 2004) to Q2 2024. Rigorous deduplication was performed, particularly focusing on eliminating overlapping information in key fields such as AE, event date, gender, age, weight, reporting country, and primary suspected active substance. To mitigate false positives arising from potential misreporting due to lack of professional knowledge, this study exclusively included reports submitted by healthcare professionals. To address issues of duplicate reporting and non-standardized drug nomenclature, the research team compiled a comprehensive list of amlodipine's drug and brand names, meticulously reorganizing drug name variants within the database. Drug entries were strictly limited to amlodipine, excluding other medications such as nimodipine. The curation process was independently conducted by two researchers, with discrepancies resolved by a third researcher. Only reports involving amlodipine as the primary suspected agent were retained for analysis.

2.2 Disproportionality analysis

To robustly ascertain the ADRs associated with amlodipine, this study employed a signal disproportionate analysis framework, integrating four risk signal detection methodologies: Ratio of Odds Ratio (ROR) (15), Proportional Reporting Ratio (PRR) (16), Bayesian Confidence Propagation Neural Network (BCPNN) (17), and Empirical Bayes Geometric Mean (EGBM) (18). The detection criteria are delineated in Table 1. For this study, an ADR was deemed a potential adverse reaction to amlodipine only if all four algorithms identified a signal for that specific ADR. Furthermore, the analysis was stratified by gender and age, facilitating subgroup analyses that subsequently identified both common and unique ADRs within different populations, thereby providing evidence for the refined monitoring of various clinical cohorts. The flowchart illustrating this process can be found in Figure 1.

3 Results

3.1 Basic characteristics

Between the first quarter of 2004 and the second quarter of 2024, we retrieved 18,886 reports from the FAERS database, wherein amlodipine was designated as the primary suspect (PS). Among these reports, a majority were from female patients (48.6%), with individuals aged 65 and older constituting the predominant demographic (42.1%). This suggests that the use of amlodipine in

Category	Formula/Criteria	Target drug	Not-target drug
Target ADR		a	c
Not-target ADR		b	d
Total	$N = \mathbf{a} + \mathbf{b} + \mathbf{c} + \mathbf{d}$		
	ROR = (ad)/(bc)	PRR = [a(c+d)]/[c(a+b)]	
	95% CI = eln(ROR) + 1.96 $\sqrt{(1/a + 1/b + 1/c + 1/d)}$	$X^{2} = N(ad-bc)2/[(a+b)(c+d)(a+c)(b+d)$	
ROR PRR	The criteria of positive safety signal detection by ROR: the lower limit of 95% CI >1, a ${\geq}3$	The criteria of positive safety signal detection by PRR: PRR $\geq 2, X^2 \geq 4, N \geq 3$	
BCPNN	IC = log2(aN)/(a+b)(a+c)	EBGM = (aN)/[a+b)(a+c)]	
EGBM	95% CI = E(IC) $\pm 2^* \sqrt{V(IC)}$	95% CI = eln(EGBM) $\pm 1.96\sqrt{(1/a + 1/b + 1/c + 1/d)}$	
	The criteria of positive safety signal detection of BPCNN:IC025 > 0 (IC025: the lower bound of 95% CD)	The positive safety signal detection criteria by EGBM:EBGM05 > 2 (EBGM05: the lower bound of 95% CI)	

TABLE 1 Formulas and criteria for identifying safety signals in four methods.



10.3303/10/11.2023.13040/1	10.3389/f	cvm.2025	5.1504671
----------------------------	-----------	----------	-----------

TABLE 2 General characteristics table.

Variable	Amlodipine(<i>N</i> = 18,886)			
Gender				
Female	9,182 (48.6%)			
Male	7,846 (41.5%)			
Unknown	1,858 (9.8%)			
Weight				
<50 kg	398 (2.1%)			
>100 kg	702 (3.7%)			
50-100 kg	4,143 (21.9%)			
Unknown	13,643 (72.2%)			
Age				
<18	695 (3.7%)			
≥86	1,217 (6.4%)			
18-64	7,170 (38.0%)			
65-85	6,737 (35.7%)			
Unknown	3,067 (16.2%)			
Reporter				
Health Professional	5,291 (28.0%)			
Medical Doctor	10,038 (53.2%)			
Pharmacist	3,549 (18.8%)			
Registered Nurse	8 (0.0%)			
Top 5 Reporting Countries				
	United States			
	United Kingdom			
	Canada			
	France			
	Italy			

the elderly population warrants significant attention. The top five reporting countries were the United States, United Kingdom, Canada, France, and Italy, with detailed results presented in Table 2.

3.2 Identification of signal for ADRs in the entire population

Based on 18,886 reports from the entire population, we utilized a combination of four methodologies to identify ADR signals associated with amlodipine, resulting in a total of 513 potential ADRs. The top five, ranked by ROR, were as follows: Hypoinsulinaemia [a: 7, ROR (95% CI lower limit): 85.321, PRR (X²): 243.233 (844.330), IC025: 5.107, EBGM (95% CI lower limit): 351.393]; Gingival Hypoplasia [a: 4, ROR (95% CI lower limit): 52.253, PRR (X²): 194.586 (427.981), IC025: 4.863, EBGM (95% CI lower limit): 142.440]; Gingival Hypertrophy [a: 305, ROR (95% CI lower limit): 156.244, PRR (X²): 180.501 (31253.613), IC025: 5.032, EBGM (95% CI lower limit): 27,606.370]; Subepidermal Haemorrhage [a: 5, ROR (95% CI lower limit): 41.57, PRR (X²): 121.616 (398.749), IC025: 4.532, EBGM (95% CI lower limit): 162.398]; and Increased Body Fluid [a: 4, ROR (95% CI lower limit): 36.622, PRR (X²): 121.616 (318.999), IC025: 4.499, EBGM (95% CI lower limit): 116.849]. The results for the top 50 are illustrated in Figure 2A.

When mapped to the System Organ Class (SOC) level, the potential ADRs associated with amlodipine in the general population predominantly encompassed Investigations (15.59%),

Cardiac Disorders (8.38%), Nervous System Disorders (7.80%), Gastrointestinal Disorders (6.43%), and Respiratory, Thoracic and Mediastinal Disorders (5.85%) (Figure 2B).

3.3 Identification of signal for ADRs in male population

Based on 7,846 reports from the male population, we employed a combination of four methodologies to identify ADR signals associated with amlodipine, resulting in a total of 348 potential ADRs. The top five, ranked by ROR, were as follows: Electrocardiogram J Wave [a: 6, ROR (95% CI lower limit): 93.112, PRR (X²): 329.913 (787.000), IC025: 5.171, EBGM (95% CI lower limit): 273.027]; Increased Body Fluid [a: 4, ROR (95% CI lower limit): 47.252, PRR (X²): 175.954 (386.577), IC025: 4.718, EBGM (95% CI lower limit): 128.656]; Gingival Hypoplasia [a: 3, ROR (95% CI lower limit): 36.92, PRR (X²): 164.957 (279.365), IC025: 4.612, EBGM (95% CI lower limit): 79.831]; Cockroach Allergy [a: 3, ROR (95% CI lower limit): 36.92, PRR (X²): 164.957 (279.365), IC025: 4.612, EBGM (95% CI lower limit): 79.831]; and Gingival Hypertrophy [a: 129, ROR (95% CI lower limit): 112.535, PRR (X²): 139.766 (10,867.624), IC025: 4.750, EBGM (95% CI lower limit): 9,033.000]. The results for the top 50 are illustrated in Figure 3A.

When mapped to the SOC level, the potential ADRs associated with amlodipine in the male population predominantly encompassed Investigations (16.95%), Cardiac Disorders (10.06%), Respiratory, Thoracic and Mediastinal Disorders (8.91%), Gastrointestinal Disorders (7.47%), and Skin and Subcutaneous Tissue Disorders (6.90%) (Figure 3B).

3.4 Identification of signal for ADRs in female population

Based on 9,182 reports from the female population, we employed a combination of four methodologies to identify ADR signals associated with amlodipine, resulting in a total of 403 potential ADRs. The top five, ranked by ROR, were as follows: Friedreich's Ataxia [a: 4, ROR (95% CI lower limit): 72.722, PRR (X²): 324.912 (553.570), IC025: 5.174, EBGM (95% CI lower limit): 158.189]; Gingival Hypertrophy [a: 143, ROR (95% CI lower limit): 187.73, PRR (X²): 235.452 (16,979.403), IC025: 5.235, EBGM (95% CI lower limit): 14,006.495]; Malpositioned Teeth [a: 7, ROR (95% CI lower limit): 77.329, PRR (X²): 213.224 (788.587), IC025: 5.020, EBGM (95% CI lower limit): 337.452]; Congenital Acrochordon [a: 5, ROR (95% CI lower limit): 61.979, PRR (X²): 203.070 (548.387), IC025: 4.935, EBGM (95% CI lower limit): 203.137]; and Rectourethral Fistula [a: 5, ROR (95% CI lower limit): 61.979, PRR (X²): 203.070 (548.387), IC025: 4.935, EBGM (95% CI lower limit): 203.137]. The results for the top 50 are illustrated in Figure 4A.

When mapped to the SOC level, the potential ADRs associated with amlodipine in the female population predominantly encompassed Investigations (14.14%), Nervous System Disorders

ADK		ROR(95%CI)	PRR(X ²)	IC025	EBGM(95% Lower Lin
GINGIVAL HYPERTROPHY	1	 181.222 (156.244 - 210.192)	180.501 (31253.613)	5.032	31253.613 (27606.370
VASOPLEGIA SYNDROME		83.317 (71.116 - 97.610)	83.094 (12454.053)	4.290	12454.053 (10908.70
DISTRIBUTIVE SHOCK		79.109 (68.099 - 91.900)	78.877 (13180.552)	4.234	13180.552 (11627.09
BRASH SYNDROME	-	20.941 (15.817 - 27.726)	20.928 (926.050)	2.605	926.050 (732.227)
SUBACUTE CUTANEOUS LUPUS ERYTHEMATOS	U\$ -	17.062 (13.131 - 22.169)	17.049 (847.128)	2.331	847.128 (680.449)
SEDATION COMPLICATION	+	15.779 (12.717 - 19.578)	15.762 (1142.668)	2.226	1142.668 (953.961)
PERIODONTITIS	•	15.504 (11.942 - 20.129)	15.493 (764.758)	2.202	764.758 (614.689)
GINGIVAL SWELLING	•	15.144 (11.831 - 19.385)	15.131 (832.502)	2.170	832.502 (677.123)
SCHIZOAFFECTIVE DISORDER	+	14.450 (10.893 - 19.169)	14.441 (602.298)	2.106	602.298 (475.474)
SHOCK		13.133 (12.015 - 14.356)	13.052 (5431.575)	1.971	5431.575 (5041.667)
ORTHOSTATIC HYPOTENSION		13.122 (11.882 - 14.491)	13.056 (4365.552)	1.971	4365.552 (4017.635
COMPLETED SUICIDE		12.452 (11.885 - 13.046)	12.167 (18594.943)	1.874	18594,943 (17883,49
INTENTIONAL OVERDOSE		11,162 (10,492 - 11,876)	11.021 (9260.762)	1,738	9260 762 (8793 056)
CREATININE RENAL CLEARANCE DECREASED		10 768 (8 776 - 13 212)	10 756 (813 588)	1 703	813 588 (685 610)
HAEMODYNAMIC INSTABILITY		9 917 (8 379 - 11 738)	9 901 (1084 315)	1 589	1084 315 (941 695)
CARDIOGENIC SHOCK		9.373(8.285 - 10.604)	9 344 (1887 887)	1 509	1887 887 (1702 734
BLOOD LACTIC ACID INCREASED		7 266 (5 643 - 9 355)	7 261 (325 037)	1 157	325 037 (263 088)
HYPOTENSION		7109(6804-7428)	6 940 (10453 220)	1 094	10453 220 (10076 12
GINGIVITIS		6850(5213-9001)	6 846 (257 372)	1.074	257 372 (204 708)
		6.363(5.213 - 9.001)	6 323 (2462 127)	0.064	237.372 (204.790)
	-	5.303(5.850 - 0.920)	0.323 (2402.127) 5.039 (247.062)	0.904	2402.127 (2293.004)
		5.955 (4.790 - 7.540)	5.920 (347.902)	0.072	347.902 (291.200)
		5.759 (5.307 - 6.246)	5.721 (2200.120)	0.023	2200.120 (2110.419)
	•	5.679 (5.102 - 6.321)	5.658 (1290.123)	0.807	1290.123 (1179.504)
OVERDOSE	•	5.592 (5.238 - 5.970)	5.536 (3383.626)	0.776	3383.626 (3203.372
	•	5.559 (4.597 - 6.722)	5.552 (397.860)	0.780	397.860 (339.381)
	•	5.524 (4.461 - 6.842)	5.519 (311.243)	0.771	311.243 (260.247)
BLOOD CALCIUM DECREASED	•	5.503 (4.485 - 6.752)	5.497 (338.292)	0.766	338.292 (285.075)
OBSTRUCTIVE AIRWAYS DISORDER	•	5.341 (4.413 - 6.464)	5.335 (372.351)	0.724	372.351 (317.411)
OLIGURIA	•	5.321 (4.102 - 6.903)	5.318 (199.005)	0.719	199.005 (160.063)
PEMPHIGOID		5.082 (4.061 - 6.361)	5.078 (250.286)	0.654	250.286 (207.450)
ERECTILE DYSFUNCTION	•	4.911 (4.089 - 5.898)	4.905 (356.651)	0.605	356.651 (305.975)
ACUTE RESPIRATORY DISTRESS SYNDROME	•	4.543 (3.898 - 5.296)	4.535 (452.045)	0.494	452.045 (397.644)
BLOOD PRESSURE DIASTOLIC DECREASED	•	4.405 (3.521 - 5.512)	4.402 (201.470)	0.452	201.470 (167.031)
OEDEMA PERIPHERAL		4.342 (4.039 - 4.668)	4.309 (1889.651)	0.422	1889.651 (1778.702)
LACTIC ACIDOSIS	•	4.324 (3.833 - 4.877)	4.312 (675.402)	0.423	675.402 (610.601)
NOCTURIA		4.278 (3.235 - 5.659)	4.276 (123.356)	0.410	123.356 (97.615)
CIRCULATORY COLLAPSE		4.161 (3.481 – 4.973)	4.156 (289.924)	0.370	289.924 (249.727)
FULL BLOOD COUNT ABNORMAL	•	4.126 (3.258 - 5.227)	4.124 (162.902)	0.359	162.902 (133.672)
POISONING DELIBERATE		4.077 (3.294 - 5.046)	4.074 (196.212)	0.342	196.212 (164.150)
MOTOR DYSFUNCTION		4.046 (3.060 - 5.352)	4.044 (112.729)	0.331	112.729 (89.216)
LOW BIRTH WEIGHT BABY	•	3.974 (3.066 - 5.152)	3.972 (126.915)	0.306	126.915 (102.140)
ATRIOVENTRICULAR BLOCK	•	3.959 (3.002 - 5.221)	3.957 (110.906)	0.300	110.906 (87.979)
MUSCLE SPASTICITY		3.952 (3.104 - 5.032)	3.950 (145.270)	0.298	145.270 (118.691)
CARDIOTOXICITY		3.639 (2.869 - 4.616)	3.637 (129.991)	0.181	129.991 (106.535)
DEPRESSED LEVEL OF CONSCIOUSNESS		3.626 (3.205 - 4.104)	3.618 (478.233)	0.174	478.233 (431.241)
DRUG LEVEL INCREASED		3.536 (2.943 - 4.247)	3.532 (207.603)	0.139	207.603 (178.064)
JOINT SWELLING		3.512 (3.241 - 3.806)	3.492 (1068.310)	0.123	1068.310 (998.827)
PULMONARY OEDEMA		3.509 (3.069 - 4.011)	3.502 (384.394)	0.127	384.394 (343.655)
HYPOTHERMIA	•	3.441 (2.673 - 4.431)	3.439 (104.087)	0.101	104.087 (84.241)
BALANCE DISOBDED	1	2 222 (2 844 2 857)	2 216 (260 662)	0.006	260 662 (222 605)





FIGURE 2

Positive signal detection in the entire epileptic population. (A) Forest plot of top 50 positive adverse drug reactions (ADRs). (B) System organ class (SOC) mapping chart.

	ADR			ROR(95%CI)	PRR(X ²)	IC025	EBGM(95% Lower Limit)
	GINGIVAL HYPERTROPHY			- 140.365 (112.535 - 175.078)	139.766 (10867.624)	4.750	10867.624 (9033.000)
	DISTRIBUTIVE SHOCK		-	68.977 (54.128 - 87.899)	68.782 (4376.238)	4.045	4376.238 (3572.790)
	VASOPLEGIA SYNDROME			30,765 (21,906 - 43,207)	30,727 (958,951)	3.085	958,951 (721,737)
	GINGIVAL SWELLING	+		19 724 (13 098 - 29 700)	19 708 (407 478)	2 509	407 478 (289 303)
	PEPIODONTITIS	-		15 204 (10 021 - 23 342)	15 283 (287 082)	2 170	287 082 (201 541)
		-		10.254 (10.021 - 20.042)	19.203 (201.002)	2.170	207.002 (201.341)
	COMPLETED SUICIDE	•		13.252 (12.374 - 14.193)	12.889 (9232.090)	1.946	9232.090 (8717.033)
	INTENTIONAL OVERDOSE	•		11.709 (10.576 - 12.964)	11.568 (3627.350)	1.798	3627.350 (3331.109)
	BREATH SOUNDS ABNORMAL	•		10.678 (7.675 - 14.854)	10.666 (309.144)	1.684	309.144 (234.527)
	SHOCK	•		10.044 (8.694 - 11.604)	9,986 (1501,534)	1.596	1501.534 (1330.724)
				9.207(7.743 - 10.947)	0 170 (036 822)	1 478	036 822 (810 445)
	CARDIOGENIC SHOCK	-		0.070 (1.145 10.341)	0.000 (450.500)	4.450	450 500 (444 047)
	GINGIVITIS	•		9.072 (5.977 - 13.766)	9.000 (156.529)	1.400	156.529 (111.617)
	ORTHOSTATIC HYPOTENSION	•		8.432 (7.107 - 10.004)	8.398 (860.487)	1.356	860.487 (745.771)
	DIASTOLIC DYSFUNCTION	+		8.244 (5.436 - 12.503)	8.239 (141.017)	1.326	141.017 (99.529)
	OBSTRUCTIVE AIRWAYS DISORDER			7.883 (6.209 - 10.008)	7.867 (405.230)	1.264	405.230 (331.867)
	FULL BLOOD COUNT ABNORMAL			7 423 (5 514 - 9 993)	7 414 (241 598)	1 181	241 598 (188 393)
		_		7 290 (5 204 - 10 290)	7 272 (101 990)	1 172	101 990 (145 212)
	BLOOD FRESSORE DIASTOLIC DECREASED	-		7.380 (3.294 - 10.289)	7.572 (191.869)	1.175	191.009 (140.005)
	BLOOD LACTIC ACID INCREASED	•		7.197 (4.971 - 10.420)	7.191 (149.696)	1.138	149.696 (109.835)
	HAEMODYNAMIC INSTABILITY	•		7.069 (5.333 – 9.370)	7.058 (251.984)	1.113	251.984 (199.049)
	ATRIOVENTRICULAR BLOCK SECOND DEGREE	•		7.040 (4.647 - 10.665)	7.036 (115.412)	1.106	115.412 (81.531)
	SUICIDE ATTEMPT			6913(6071 - 7871)	6 866 (1153 155)	1 075	1153 155 (1034 484)
	MICTURITION URGENCY			6 970 (4 939 - 0 792)	6 973 (155 756)	1.075	155 756 (116 016)
	MICTORITION ORGENCE			0.079 (4.030 - 9.702)	0.073 (100.100)	1.075	155.756 (110.018)
	BRUNCHIECTASIS	•		5.924 (4.146 - 8.464)	5.919 (123.415)	0.865	123.415 (91.553)
	HYPOTENSION	•		5.743 (5.348 - 6.167)	5.617 (2963.593)	0.794	2963.593 (2792.096)
	GINGIVAL BLEEDING	•		5.735 (4.119 - 7.986)	5.729 (137.000)	0.820	137.000 (103.850)
	LEET VENTRICULAR HYPERTROPHY			5.607 (3.739 - 8.410)	5.604 (88.528)	0.788	88,528 (63,066)
	SI EED DISODDED DIJE TO A CENEDAL MEDICAL CONDITION			5 465 (3 847 - 7 762)	5 460 (112 704)	0.750	113 784 (84 924)
	DALES	T		5.403 (3.047 - 1.102)	5.400 (113.784)	0.752	113.704 (04.031)
	KALES	•		5.403 (3.687 - 7.916)	5.399 (94.461)	0.736	94.401 (68.619)
	SINUS BRADYCARDIA	-		5.400 (4.111 - 7.093)	5.392 (185.117)	0.735	185.117 (147.345)
	BRADYCARDIA	•		5.380 (4.784 - 6.051)	5.338 (993.119)	0.722	993.119 (900.170)
	HYPERCHOLESTEROLAEMIA			5.020 (3.555 - 7.090)	5.016 (103 763)	0.633	103,763 (77,729)
	EPECTILE DYSELINCTION			4 692 (3 899 - 5 646)	4 678 (325 997)	0.526	325 887 (270 120)
				4.092 (3.099 - 3.040)	4.010 (323.881)	0.030	323.007 (279.139)
	MUSULE SPASTICITY	•		4.543 (3.103 - 6.652)	4.540 (73.037)	0.492	13.037 (53.089)
	POISONING DELIBERATE			4.462 (3.208 - 6.208)	4.458 (94.680)	0.467	94.680 (71.827)
	OVERDOSE	-		4.447 (3.974 - 4.977)	4.412 (811.470)	0.453	811.470 (738.588)
	OEDEMA PERIPHERAL			4 340 (3 875 - 4 861)	4 306 (768 628)	0 4 1 9	768 628 (699 082)
		-		4 240 (3 640 - 4 947)	4 230 (411 058)	0.304	411.058 (362.701)
	JOINT SWELLING			4.249 (3.649 - 4.947)	4.230 (411.936)	0.394	411.958 (362.701)
	METABOLIC ACIDOSIS			4.220 (3.530 - 5.047)	4.207 (295.379)	0.386	295.379 (254.341)
	WHEEZING	•		4.125 (3.421 - 4.975)	4.114 (259.365)	0.354	259.365 (221.747)
	BODY TEMPERATURE DECREASED	•		3.995 (2.783 - 5.733)	3.992 (66.084)	0.310	66.084 (48.845)
	TOXIC SKIN ERUPTION			3 888 (2 844 - 5 316)	3 884 (84 208)	0 272	84 208 (64 815)
	DEMOHICOID	_		2,956 (2,747 5,412)	2,952 (70,601)	0.260	70 601 (52 152)
	FEMPHIGOID			5.650 (2.747 - 5.415)	3.655 (70.001)	0.200	70.001 (55.155)
	CARDIOTOXICITY	•		3.842 (2.520 - 5.858)	3.840 (45.430)	0.255	45.430 (31.924)
	NOCTURIA	•		3.831 (2.618 - 5.606)	3.829 (55.477)	0.251	55.477 (40.345)
	MOVEMENT DISORDER			3.678 (2.633 - 5.137)	3.674 (67.033)	0.193	67.033 (50.679)
	DYSPNOEA EXERTIONAL			3.624 (2.924 - 4.491)	3 616 (158 396)	0.171	158.396 (132.357)
	ASTHMA	-		3623(3082 - 4259)	3 610 (278 864)	0.160	278 864 (243 567)
		-		0.505 (0.052 4.235)	0.570 (270.004)	0.103	210.004 (243.001)
	PULMUNART UEDEMA			3.363 (2.936 - 4.343)	3.570 (193.773)	0.155	193.773 (104.900)
	HEART RATE DECREASED	•		3.439 (2.720 - 4.349)	3.434 (120.664)	0.097	120.664 (99.150)
	BENIGN PROSTATIC HYPERPLASIA	•		3.424 (2.372 - 4.942)	3.422 (48.961)	0.092	48.961 (36.016)
	RESPIRATORY DEPRESSION			3.287 (2.432 - 4.443)	3.284 (67.325)	0.034	67.325 (52.321)
		50	400 450				
		50	100 150				
	,	and the second second					
	*	Positive ADR					
	*	Positive ADR					
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					(
	SOC Level	Positive ADR					1
	SOC Level	Positive ADR					1
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					ł
	SOC Level	Positive ADR					
	SOC Level	Positive ADR					
3	SOC Level	Positive ADR					
3	SOC Level	Positive ADR	_	Investigations/16.05%)			
3	SOC Level	Positive ADR		Investigations(16.95%)			
3	SOC Level	Positive ADR		Investigations(16.95%)			
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%)			
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory Thoracic And M	lediastinal Disordersters	8 91%)	
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M	Iediastinal Disorders(8.91%))
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7	lediastinal Disorders(47%)	8.91%))
;	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7	lediastinal Disorders(.47%)	8.91%)	
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis	lediastinal Disorders(47%) sue Disorders(6.90%	8.91%)	
;	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis	lediastinal Disorders(.47%) sue Disorders(6.90%	8.91%)	
;	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders()	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%)	8.91%)	
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%)	8.91%))
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (8.91%)) ncl Cys) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (8.91%)) ncl Cys) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Procee	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(8.91%)) 1.60%)) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And N Gastrointestinal Disorders(7 Skin And Subcutaneous Tis: Nervous System Disorders(1 Neoplasms Benign, Maligna Injury, Poisoning And Proce	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(-	8.91%)) incl Cys 4.60%)) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Procer Vascular Disorders(4.31%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4	8.91%)) Incl Cys 4.60%)) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Procee Vascular Disorders(4.31%) General Disorders And Adm	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4	8.91%)) I.60%)) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4 inistration Site Condi	8.91%)) ncl Cys 1.60%) tions(4.) sts And Polyps)(4.89%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(inistration Site Condi	8.91%)) Incl Cys I.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4 inistration Site Condi	8.91%)) ncl Cys 1.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 5.61%) nt And Unspecified (dural Complications(inistration Site Condi	8.91%)) Incl Cys I.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(1 Neoplasms Benign, Maligna Injury, Poisoning And Procer Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(inistration Site Condi	8.91%)) ncl Cys .60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(- inistration Site Condi	8.91%)) 1.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And N Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(1 Neoplasms Benign, Maligna Injury, Poisoning And Procer Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(inistration Site Condi	8.91%)) incl Cys 4.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4 inistration Site Condi	8.91%)) 1.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(1 Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(- inistration Site Condi	8.91%)) ncl Cys 4.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Procer Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(ainistration Site Condi	8.91%)) I.60%) tions(4.) sts And Polyps)(4.89%) .02%)
3	SOC Level	Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(- inistration Site Condi	8.91%)) ncl Cys .60%) tions(4.) sts And Polyps)(4.89%) .02%)
		Positive ADR		Investigations(16.95%) Cardiac Disorders(10.06%) Respiratory, Thoracic And M Gastrointestinal Disorders(7 Skin And Subcutaneous Tis Nervous System Disorders(1 Neoplasms Benign, Maligna Injury, Poisoning And Proce Vascular Disorders(4.31%) General Disorders And Adm Other(25.29%)	lediastinal Disorders(.47%) sue Disorders(6.90% 6.61%) nt And Unspecified (dural Complications(4 inistration Site Condi	8.91%)) Incl Cys 8.60%) tions(4.) sts And Polyps)(4.89%) .02%)

A	ADR		ROR(95%CI)	PRR(X ²)	IC025	EBGM(95% Lower Limit
	GINGIVAL HYPERTROPHY		- 236.285 (187.730 - 297.399)	235.452 (16979.403)	5.235	16979.403 (14006.495)
	VASOPLEGIA SYNDROME	_ -	139.131 (112.692 - 171.772)	138.666 (11846.876)	4.799	11846.876 (9931.588)
	DISTRIBUTIVE SHOCK		79.242 (63.768 - 98.472)	79.033 (6283.410)	4.233	6283.410 (5238.958)
	SEDATION COMPLICATION	•	29.040 (23.276 - 36.230)	28.979 (2124.692)	3.032	2124.692 (1765.649)
	SCHIZOAFFECTIVE DISORDER	+	26.031 (19.500 - 34.751)	26.000 (1107.818)	2.889	1107.818 (869.938)
	SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSU	s -	21,196 (15,827 - 28,385)	21,171 (866,480)	2.620	866,480 (678,613)
	CREATININE RENAL CLEARANCE DECREASED	•	19.439 (15.752 - 23.988)	19.396 (1519.325)	2,505	1519.325 (1274.201)
	ORTHOSTATIC HYPOTENSION	•	18.570 (16.294 - 21.165)	18,464 (3732,583)	2.441	3732.583 (3345.692)
	PERSONALITY DISORDER		17 386 (12 397 - 24 384)	17 372 (518 515)	2 355	518 515 (390 701)
	SHOCK		13.740 (12.064 - 15.649)	13.664 (2679.706)	2.033	2679,706 (2403,280)
	GINGIVAL SWELLING	•	13.292 (9.668 - 18.275)	13,280 (430,765)	1.991	430,765 (330,021)
	COMPLETED SUICIDE		11 452 (10 730 - 12 222)	11 200 (8634 337)	1 761	8634 337 (8176 470)
	HAEMODYNAMIC INSTABILITY		10 294 (8 030 - 13 196)	10 279 (522 489)	1 640	522 489 (424 444)
	INTENTIONAL OVERDOSE		9 954 (9 128 - 10 854)	9 834 (4124 886)	1.580	4124 886 (3836 593)
	BLOOD CALCIUM DECREASED		9.095 (7.384 - 11.202.)	9 076 (637 597)	1 468	637 597 (535 594)
	ANURIA		8 884 (6 835 - 11 547)	8 872 (390 967)	1 436	390.967 (313.953)
	CARDIOGENIC SHOCK		7 633 (6 201 - 9 395)	7.618 (513.032)	1 224	513 032 (431 174)
	HYPOTENSION		7 131 (6 693 = 7 596)	6 977 (5051 135)	1 102	5051 135 (4700 571)
	HEMIDLECIA	5	6 884 (E 404 0 200)	6.979 (344.079)	1.102	214 079 (467 295)
			6.004 (5.101 - 9.290)	0.070 (214.970)	1.000	214.970 (107.203)
	DEMOLIO OF DESCONCTION	2	6.713 (4.940 - 9.123)	0.707 (190.521)	1.045	190.321 (153.304)
			0.570(4.705 - 9.042)	0.572 (179.445)	1.010	702 457 (704 240)
	METABOLIC ACIDOSIS		6.308 (5.445 - 7.307)	0.204 (793.157)	0.954	793.157 (701.319)
	OVERDOSE	•	6.293 (5.740 - 6.898)	6.231 (2024.857)	0.943	2024.857 (1875.006)
	DRUG LEVEL INCREASED	•	5.985 (4.825 - 7.423)	5.974 (343.748)	0.883	343.748 (287.055)
	SEDATION		5.868 (4.864 - 7.079)	5.854 (440.447)	0.855	440.447 (376.441)
	BRADYCARDIA		5.834 (5.150 - 6.608)	5.803 (991.251)	0.843	991.251 (893.126)
	ACUTE RESPIRATORY DISTRESS SYNDROME		5./12(4.61/-7.06/)	5.702 (329.757)	0.817	329.757 (275.971)
	CIRCULATORY COLLAPSE		5.455 (4.345 - 6.849)	5.447 (269.991)	0.753	269.991 (223.185)
	LACTIC ACIDOSIS		5.440 (4.641 - 6.377)	5.423 (550.893)	0.747	550.893 (482.282)
	SUICIDE ATTEMPT		5.387 (4.768 - 6.087)	5.358 (920.302)	0.730	920.302 (830.914)
	GINGIVAL BLEEDING		5.222 (3.873 - 7.041)	5.218 (146.893)	0.692	146.893 (114.400)
	BLOOD PRESSURE DIASTOLIC DECREASED	•	5.137 (3.784 - 6.974)	5.133 (136.904)	0.668	136.904 (106.000)
	COORDINATION ABNORMAL	•	4.575 (3.259 - 6.425)	4.572 (93.168)	0.505	93.168 (70.134)
	COGNITIVE DISORDER	•	4.564 (3.825 - 5.445)	4.553 (343.162)	0.500	343.162 (296.046)
	BALANCE DISORDER		4.351 (3.773 - 5.018)	4.335 (487.076)	0.430	487.076 (432.267)
	MUSCLE SPASTICITY	•	4.275 (3.127 - 5.844)	4.271 (98.518)	0.409	98.518 (75.834)
	SINUS BRADYCARDIA	•	4.195 (3.056 - 5.758)	4.192 (93.217)	0.382	93.217 (71.517)
	OEDEMA PERIPHERAL	•	4.175 (3.780 - 4.611)	4.143 (940.232)	0.366	940.232 (865.255)
	PRODUCT DISPENSING ERROR	-	4.160 (2.992 - 5.785)	4.158 (84.904)	0.370	84.904 (64.441)
	DEPRESSED LEVEL OF CONSCIOUSNESS		4.141 (3.519 - 4.873)	4.129 (345.440)	0.361	345.440 (301.457)
	AFFECT LABILITY	•	3.942 (2.822 - 5.506)	3.939 (75.561)	0.294	75.561 (57.133)
	SINUS CONGESTION	•	3.932 (2.876 - 5.374)	3.929 (85.970)	0.290	85.970 (66.187)
	HYPOXIA	•	3.922 (3.278 - 4.691)	3.913 (260.565)	0.285	260.565 (224.295)
	TACHYPNOEA	-	3.915 (2.906 - 5.274)	3.912 (93.885)	0.284	93.885 (73.165)
	EATING DISORDER	•	3.851 (2.878 - 5.154)	3.848 (95.487)	0.261	95.487 (74.825)
	OBSTRUCTIVE AIRWAYS DISORDER	•	3.764 (2.732 - 5.186)	3.761 (75.876)	0.228	75.876 (58.026)
	HYPERGLYCAEMIA		3.578 (2.908 - 4.402)	3.572 (166.203)	0.155	166.203 (139.748)
	BLOOD PRESSURE FLUCTUATION	•	3.548 (2.766 - 4.551)	3.544 (113.443)	0.144	113.443 (92.114)
	URINARY RETENTION	•	3.381 (2.620 - 4.363)	3.377 (99.084)	0.075	99.084 (80.048)
			3 226 (2 902 = 3 585)	3 206 (528 935)	0.002	528 035 (484 200)

50 100 150 200 250
Positive ADR

В

SOC Level



(8.44%), Gastrointestinal Disorders (7.69%), Cardiac Disorders (6.70%), and Respiratory, Thoracic and Mediastinal Disorders (6.20%) (Figure 4B).

3.5 Identification of signal for ADRs in elderly population

Based on 7,954 reports from the elderly population, we employed a combination of four methodologies to identify ADR signals associated with amlodipine, resulting in a total of 246 potential ADRs. The top five, ranked by ROR, were as follows: Cockroach Allergy [a: 3, ROR (95% CI lower limit): 50.214, PRR (X²): 482.675 (360.509), IC025: 4.817, EBGM (95% CI lower limit): 54.258]; Increased Body Fluid [a: 3, ROR (95% CI lower limit): 40.331, PRR (X²): 241.338 (287.211), IC025: 4.561, EBGM (95% CI lower limit): 64.266]; Gingival Hypertrophy [a: 31, ROR (95% CI lower limit): 107.086, PRR (X²): 178.130 (2,591.359), IC025: 4.703, EBGM (95% CI lower limit): 1,689.381]; Burning Feet Syndrome [a: 3, ROR (95% CI lower limit): 32.477, PRR (X²): 160.892 (238.348), IC025: 4.348, EBGM (95% CI lower limit): 62.464]; and Acute Biphenotypic Leukaemia [a: 5, ROR (95% CI lower limit): 40.929, PRR (X²): 134.076 (360.231), IC025: 4.339, EBGM (95% CI lower limit): 133.429]. The results for the top 50 are illustrated in Figure 5A.

When mapped to the SOC level, the potential ADRs associated with amlodipine in the elderly population predominantly encompassed Investigations (13.82%), Respiratory, Thoracic and Mediastinal Disorders (9.35%), Skin and Subcutaneous Tissue Disorders (8.54%), Gastrointestinal Disorders (7.72%), and Injury, Poisoning and Procedural Complications (7.32%) (Figure 5B).

3.6 Identification of signal for ADRs in younger population

Based on 7,865 reports from the younger population, we employed a combination of four methodologies to identify ADR signals associated with amlodipine, resulting in a total of 260 potential ADRs. The top five ranked by ROR were as follows: Electrocardiogram J Wave [a: 6, ROR (95% CI lower limit): 90.682, PRR (X²): 321.255 (766.221), IC025: 5.133, EBGM (95% CI lower limit): 265.807]; Hypoinsulinaemia [a: 3, ROR (95% CI lower limit): 53.685, PRR (X²): 321.255 (383.110), IC025: 4.972, EBGM (95% CI lower limit): 85.726]; Adrenal Cyst [a: 3, ROR (95% CI lower limit): 53.685, PRR (X²): 321.255 (383.110), IC025: 4.972, EBGM (95% CI lower limit): 85.726]; Gingival Hypoplasia [a: 3, ROR (95% CI lower limit): 43.231, PRR (X²): 214.170 (318.262), IC025: 4.758, EBGM (95% CI lower limit): 83.409]; and Oropharyngeal Oedema [a: 5, ROR (95% CI lower limit): 54.48, PRR (X²): 178.475 (481.312), IC025: 4.749, EBGM (95% CI lower limit): 178.280]. The results for the top 50 are illustrated in Figure 6A.

When mapped to the SOC level, the potential ADRs associated with amlodipine in the younger population predominantly

encompassed Investigations (17.31%), Cardiac Disorders (12.69%), Respiratory, Thoracic and Mediastinal Disorders (7.69%), Gastrointestinal Disorders (7.31%), and Neoplasms— Benign, Malignant, and Unspecified (including Cysts and Polyps) (5.38%) (Figure 6B).

4 Intersection analysis

Through intersection analysis across various subgroup populations (the entire population, male population, female population, elderly population, and younger population), we identified 27 common ADRs associated with amlodipine: gingival hypertrophy, vasoplegia syndrome, distributive shock, myocardial depression, hyperdynamic left ventricle, sinus rhythm, gingival swelling, hyperplasia, shock, orthostatic hypotension, completed intentional overdose, hemodynamic instability, suicide. hypotension, gingivitis, suicide attempt, bradycardia, dyspnea at rest, metabolic acidosis, overdose, left ventricular hypertrophy, sinus bradycardia, gingival bleeding, obstructive airway disorder, gingival pain, decreased diastolic blood pressure, and peripheral edema. The primary focus of these ADRs is within the domains of cardiac disorders, respiratory issues, and dental and gingival conditions (Figure 7).

5 Multivariable logistic regression

To further ascertain whether the potential ADRs associated with amlodipine exert independent effects, we subsequently employed multivariable logistic regression, treating each of the 27 potential ADRs as binary outcome variables. The results indicate that amlodipine serves as an independent risk factor for the occurrence of all 27 potential ADRs (OR > 1), with statistically significant findings (P < 0.05). This suggests that these associations are not influenced by age or gender, aligning with the previously reported results (Figure 8).

6 Discussion

Amlodipine, a calcium channel blocker widely used in the treatment of hypertension and coronary artery disease, has demonstrated superior efficacy in controlling blood pressure variability compared to other calcium channel blockers. It has also shown cost-effectiveness relative to conventional therapies, leading to its recommendation as a preferred medication for patients with coronary artery disease (CAD) (19). Despite being recommended as a first-line therapy for hypertension, its use is constrained by potential side effects, and it has been reported as a primary cause of cardiovascular drug-related overdose deaths in the United States (20). Consequently, post-marketing surveillance of medications is crucial, particularly for commonly prescribed drugs like amlodipine.

This study represents the first comprehensive investigation of potential ADRs associated with amlodipine using the FAERS

A	ADK		ROR(95%CI)	PRR(X ²)	IC025	EBGM(95% Lower Limi
	GINGIVAL HYPERTROPHY		- 178.560 (107.086 - 297.741)	178.130 (2591.359)	4.703	2591.359 (1689.381)
	CONGENITAL HIATUS HERNIA		45.391 (27.628 - 74.574)	45.322 (676.382)	3.460	676.382 (446.455)
	MALIGNANT MELANOMA IN SITU	-	22.137 (13.521 - 36.243)	22.107 (318.946)	2.607	318.946 (211.138)
	INTENTIONAL OVERDOSE	•	15.823 (12.048 - 20.782)	15.757 (717.740)	2.182	717.740 (571.366)
	SPLENIC RUPTURE		14.848 (8.411 - 26.213)	14.834 (153.572)	2.090	153.572 (95.448)
	BREATH SOUNDS ABNORMAL	•	14.748 (10.144 - 21.442)	14.716 (351.433)	2.089	351.433 (256.946)
	BRASH SYNDROME	-	14.238 (8.904 - 22.768)	14.218 (214.551)	2.040	214.551 (144.859)
	COMPLETED SUICIDE	•	14.168 (12.357 - 16.244)	13.935 (2511.654)	2.023	2511.654 (2240.121)
	HYPERCHOLESTEROLAEMIA	•	13.208 (9.042 - 19.294)	13.180 (301.771)	1.943	301.771 (219.766)
	ATRIOVENTRICULAR BLOCK SECOND DEGREE		10.300 (0.733 - 15.958)	10.350 (174.620)	1.618	1/4.620 (121.705)
	DESIT		9.474 (5.627 - 15.952)	9.404 (107.254)	1.494	107.254 (09.355)
	MICTURITION URCENCY	-	9.231 (0.303 - 13.313)	9.213 (193.939)	1.401	193.939 (140.900)
			8.621 (5.557 - 14.003)	0.010 (124.733)	1.390	124.733 (04.732)
		-	8 230 (6 746 - 10 039)	9 172 (617 573)	1.303	220.474 (170.314)
	OBSTRUCTIVE AIRWAYS DISORDER		8 177 (5 972 - 11 196)	8 154 (245 029)	1 206	245 029 (188 375)
	BLOOD PRESSURE DIASTOLIC DECREASED		7 916 (5 296 - 11 831)	7 902 (143 703)	1 251	143 703 (102 665)
	JOINT INJURY		6429(4012 - 10301)	6 421 (79 244)	0.964	79 244 (53 414)
	FULL BLOOD COUNT ABNORMAL		5 996 (3 988 - 9 015)	5 987 (96 144)	0.868	96 144 (68 347)
	JOINT SWELLING		5 857 (4 683 - 7 326)	5 827 (309 034)	0.833	309.034 (256.270)
	ATRIOVENTRICULAR BLOCK FIRST DEGREE		5 693 (3 340 - 9 704)	5 688 (52 258)	0.795	52 258 (33 447)
	ASTHMA		5.545 (4.409 - 6.974)	5.518 (272 116)	0.757	272.116 (224 607)
	BODY TEMPERATURE DECREASED	•	5.360 (3.393 - 8 469)	5.354 (65 121)	0.712	65.121 (44 412)
	SHOCK		5.264 (3.970 - 6.981)	5.248 (166 606)	0.687	166,606 (131,565)
	HYPOTHERMIA		5.216 (3.170 - 8 585)	5.211 (52 752)	0.674	52,752 (34 770)
	HAEMODYNAMIC INSTABILITY	-	4.973 (3.110 - 7.952)	4.967 (55.346)	0.607	55.346 (37.370)
	SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITIO	N	4.912 (2.885 - 8.362)	4.907 (42.277)	0.589	42.277 (27.087)
	HEART RATE DECREASED	5	4.882 (3.693 - 6.454)	4.867 (152.215)	0.581	152.215 (120.511)
	DIPLOPIA		4.864 (3.240 - 7.304)	4.857 (71.386)	0.577	71.386 (50.806)
	ECZEMA	-	4.810 (3.482 - 6.645)	4.799 (111.040)	0.561	111.040 (84.734)
	ERECTILE DYSFUNCTION	•	4.792 (2.998 - 7.661)	4.787 (52.382)	0.556	52.382 (35.376)
	TOXIC SKIN ERUPTION		4.773 (3.338 - 6.825)	4.764 (89.579)	0.551	89.579 (66.413)
	DRUG ABUSE		4.728 (3.176 - 7.040)	4.721 (71.261)	0.537	71.261 (51.073)
	HYPOTENSION	•	4.676 (4.216 - 5.187)	4.567 (1033.689)	0.494	1033.689 (947.849)
	BENIGN PROSTATIC HYPERPLASIA	•	4.525 (3.063 - 6.684)	4.517 (69.297)	0.476	69.297 (49.997)
	DYSPNOEA EXERTIONAL	-	4.333 (3.385 - 5.547)	4.316 (161.475)	0.413	161.475 (131.329)
	PRODUCT PRESCRIBING ERROR	•	4.304 (3.011 - 6.151)	4.296 (76.397)	0.406	76.397 (56.663)
	SINUS BRADYCARDIA	•	4.201 (2.776 - 6.358)	4.196 (54.582)	0.372	54.582 (38.590)
	OVERDOSE		4.154 (3.296 - 5.235)	4.135 (171.755)	0.353	171.755 (141.519)
	WHEEZING	•	4.149 (3.188 - 5.400)	4.135 (132.216)	0.353	132.216 (106.055)
	OEDEMA PERIPHERAL	•	4.131 (3.553 – 4.803)	4.088 (401.731)	0.338	401.731 (354.160)
	LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	•	4.089 (2.862 - 5.843)	4.082 (70.381)	0.334	70.381 (52.212)
	RALES		4.077 (2.398 - 6.931)	4.073 (31.669)	0.329	31.669 (20.313)
	PEMPHIGOID	•	3.922 (2.745 - 5.603)	3.915 (65.725)	0.275	65.725 (48.765)
	BRADYCARDIA		3.790 (3.187 - 4.508)	3.762 (262.234)	0.220	262.234 (226.807)
	SKIN LESION		3.679 (2.454 - 5.516)	3.674 (45.690)	0.185	45.690 (32.557)
	THERAPEUTIC PRODUCT EFFECT INCOMPLETE		3.419 (2.517 - 4.644)	3.411 (70.163)	0.082	70.163 (54.308)
	GASTROUESOPHAGEAL REFLUX DISEASE		3.417 (2.432 - 4.801)	3.410 (56.766)	0.081	56.766 (42.706)
	METABOLIC ACIDOSIS		3.393 (2.555 - 4.505)	3.384 (80.674)	0.070	80.674 (63.640)
	DRUG INTERACTION	•	3.389 (2.978 - 3.857)	3.345 (387.016)	0.055	387.016 (347.334)
		50 100 150 200 250				
		Positive ADR	>			
В	SOC Level					
	SOC Level					
			Investiget	iona(12,920/)		
			Investigat	10115(13.02%)		
			Respirato	ry, Thoracic And M	lediastir	nal Disorders(9.35%)
			0	0		
			Skin And	Supcutaneous Tise	sue Dise	oraers(8.54%)
			Gastrointe	estinal Disorders(7	72%)	
			Custoline	2		a substance of the second s
			Injury, Poi	soning And Procee	dural Co	omplications(7.32%)
			Cardiac D	isorders(6.91%)		
				10010010(0.0170)		
					10011	
			Nervous S	System Disorders(6	5.10%)	
			Nervous S	System Disorders(5.10%)	

General Disorders And Administration Site Conditions(5.69%) Infections And Infestations(4.07%)

Other(24.39%)

FIGURE 5

Positive signal detection in elderly epileptic population. (A) Forest plot of positive ADRs. (B) SOC mapping chart.

L HYPERTROPHY UTIVE SHOCK FATIGUE SSTIC GIA SYNDROME DNITHS DNICB LADDER NICE CAN M			ROR(95%CI)	PRR(X ²)	IC025	EBGM(95% Lower Limit)
JTIVE SHOCK FATIGUE ISTIC GIA SYNDROME DNITHS DNICB LADDER NICE DLADDER			128.474 (99.330 - 166.169)	127.678 (7323.669)	4.652	7323.669 (5905.209)
FATIGUE ASTIC GIA SYNDROME DNTITIS DNIC BLADDER NICE DLADER	-	•	90.276 (69.830 - 116.707)	89.778 (5134.723)	4.315	5134.723 (4141.886)
ASTIC EGIA SYNDROME INITIS INIC BLADDER	· · · · · · · · · · · · · · · · · · ·		61.924 (33.400 - 114.810)	61.871 (604.048)	3.884	604.048 (360.353)
EGIA SYNDROME DNTITIS DNIC BLADDER NEODIA SM	· -•		39.808 (22.019 - 71.969)	39.774 (414.439)	3.379	414.439 (252.510)
ONTITIS ONIC BLADDER	·		35.539 (23.643 - 53.420)	35.476 (776.108)	3.255	776.108 (551.846)
ONIC BLADDER			30.054 (19.231 - 46.968)	30.011 (541.177)	3.045	541.177 (372.471)
NEODLACM			24.022 (13.538 - 42.625)	24.002 (257.697)	2.753	257.697 (159.482)
NEUPLASM			16.748 (9.900 - 28.332)	16.732 (205.812)	2.285	205.812 (132.566)
SENIC SHOCK	+		15.854 (13.141 - 19.126)	15.736 (1517.711)	2.213	1517.711 (1297.187)
IC DYSFUNCTION			13.347 (8.053 - 22.122)	13.334 (171.853)	1.981	171.853 (112.601)
	•		12.962 (10.901 - 15.413)	12.852 (1413.690)	1.939	1413.690 (1223.007)
TED SUICIDE			12.655 (11.678 - 13.713)	12.141 (6380.556)	1.863	6380.556 (5965.886)
ONAL OVERDOSE	· •		12.038 (10.757 - 13.472)	11.796 (3068.375)	1.823	3068.375 (2792.680)
ACTIC ACID INCREASED	-		11.022 (7.429 - 16.353)	11.005 (224.966)	1.724	224.966 (161.723)
YNAMIC INSTABILITY			8.131 (5.679 - 11.643)	8.116 (186.416)	1.305	186.416 (138.047)
BRANCH BLOCK LEFT	-		7.655 (4.491 - 13.049)	7.649 (78.135)	1.219	78.135 (50.007)
ATTEMPT			7.291 (6.299 - 8.439)	7.212 (974.887)	1.143	974,887 (862,610)
ARDIA			6.453 (5.472 - 7.609)	6.399 (651.225)	0.976	651.225 (567.317)
ULAR HYPOKINESIA	-		6.187 (3.636 - 10.528)	6.182 (59.119)	0.923	59.119 (37.892)
IA	-		6.171 (3.693 - 10.314)	6 166 (63 118)	0.919	63 118 (41 071)
NTRICULAR HYPERTROPHY	+		6.113 (3.658 - 10.215)	6.108 (62.303)	0.906	62.303 (40.543)
RADYCARDIA			6 112 (4 250 - 8 789)	6 102 (124 465)	0.907	124 465 (91 842)
NSION			6 036 (5 441 - 6 696)	5 909 (1498 641)	0.864	1498 641 (1374 026)
E DYSELINCTION			5,050(3.441 - 0.050)	5.003 (1430.041)	0.871	312 288 (258 576)
			5.000 (4.704 - 7.479)	5.040 (312.200)	0.960	115 147 (94 529)
	1		5.919 (4.091 - 8.303)	5.910 (115.147)	0.002	77 502 (52 404)
			5.010 (3.731 - 9.0/5)	5.012 (11.593)	0.838	107 505 (33.494)
	-		5.761 (3.970 - 8.417)	5.772 (107.595)	0.829	107.595 (78.571)
ART UEDEMA	•		5.581 (4.461 - 6.982)	5.556 (287.994)	0.777	267.994 (238.784)
AEGALY			5.402 (3.686 - 7.917)	5.394 (94.307)	0.734	94.307 (68.491)
JCARDIOGRAM QRS COMPLEX PROLONGE	0		5.397 (3.175 - 9.175)	5.393 (48.873)	0.731	48.873 (31.350)
OXICITY			5.388 (3.417 - 8.497)	5.383 (66.153)	0.730	66.153 (45.186)
SPASTICITY	•		4.940 (3.170 - 7.698)	4.935 (61.352)	0.608	61.352 (42.329)
SE	•		4.932 (4.320 - 5.631)	4.872 (685.259)	0.593	685.259 (613.317)
PERIPHERAL	-		4.443 (3.714 - 5.316)	4.415 (318.921)	0.453	318.921 (274.498)
L BLEEDING	•		4.393 (2.587 - 7.459)	4.390 (35.921)	0.442	35.921 (23.065)
ID VALVE INCOMPETENCE	-		4.274 (2.518 - 7.256)	4.271 (34.396)	0.403	34.396 (22.089)
ACIDOSIS	•		4.238 (3.288 - 5.464)	4.225 (147.415)	0.391	147.415 (119.197)
S	•		4.078 (2.486 - 6.689)	4.075 (36.437)	0.337	36.437 (24.082)
LIC ACIDOSIS) -		4.054 (3.181 - 5.165)	4.040 (150.584)	0.327	150.584 (122.957)
CTIVE AIRWAYS DISORDER			4.049 (2.468 - 6.641)	4.046 (36.016)	0.327	36.016 (23.805)
ESPIRATORY DISTRESS SYNDROME	-		3.991 (2.980 - 5.345)	3.982 (100.934)	0.307	100.934 (79.048)
NG DELIBERATE	-		3.967 (2.746 - 5.730)	3.961 (63.057)	0.299	63.057 (46.359)
TORY COLLAPSE			3.907 (2.650 - 5.761)	3,902 (55,140)	0.277	55,140 (39,847)
VALVE INCOMPETENCE	-		3.664 (2.299 - 5.840)	3,661 (34,241)	0,186	34,241 (23,182)
WELLING			3 652 (2 918 - 4 570)	3 638 (146 919)	0 179	146 919 (121 770)
TORY DEPRESSION			3 639 (2 551 - 5 192)	3 634 (58 230)	0 177	58 230 (43 252)
			3 626 (2 244 - 5 857)	3 623 (31 753)	0 171	31 753 (21 256)
N ERACTION DECREASED	5		3 618 (2 395 - 5 465)	3 614 (42 783)	0 168	42 783 (30 297)
ARY CONGESTION			3377(2027 - 5625)	3 375 (24 682)	0.070	24 682 (16 104)
ION ERBOR			3 269 (2 372 - 4 505)	3 263 (58 798)	0.024	58 798 (44 957)
		100 150	,	,,		,
	50	100 150				
	Positive ADR					
SOC Level						
		_				
			Investigations(17.31%)			
			Cardiac Disorders(12.69%	6)		
			,			
			Respiratory, Thoracic And	Mediastinal Disord	ers(7.69	1%)
			Gastrointestinal Disorders	(7 31%)		
			Castron testinar Disordere	(1.0170)		
			Neoplasms Benign, Malig	nant And Unspecifie	ed (Incl C	Cysts And Polyps)(5.38%)
			General Disorders And A	Iministration Olt- O	ndition	(5.00%)
			General Disorders And A	ammistration Site Co	nultions	5(0.00%)
			Injury, Poisoning And Pro	cedural Complication	ns(5.00%	%)
						,
			Nervous System Disorder	s(5.00%)		
		y 🗖	Infections And Infestation	s(4.62%)		
			Skin And Subcutaneous 1	issue Disorders(4.6	2%)	
			Other(25,38%)			
			01101120.00701			
				Skin And Subcutaneous T Other(25.38%)	Skin And Subcutaneous Tissue Disorders(4.6	Skin And Subcutaneous Tissue Disorders(4.62%) Other(25.38%)



database. Employing disproportionality analysis, a rapid and economical method, we identified 27 common potential risks across various subgroups (including the general population, males, females, elderly, and younger individuals), which appear to be independent of age and gender. These findings were further validated through multivariable logistic regression, emphasizing their independence. This underscores the importance of vigilant monitoring for these potential ADRs in clinical applications of amlodipine, providing crucial evidence for clinical decision-making.

Peripheral edema, characterized by fluid retention in the extremities or other body parts, is a widely recognized and common adverse effect of amlodipine. It is generally attributed to the dilation of precapillary arterioles in the lower limbs, where increased hydrostatic pressure promotes fluid transfer into interstitial spaces. Amlodipine is used both as monotherapy and in combination with other antihypertensive medications. As monotherapy, statistical analyses indicate that amlodipine induces peripheral edema in 16.6% of cases (21), a higher incidence compared to other antihypertensive drugs (22). A specific clinical trial also found higher rates of peripheral and pulmonary edema

in patients receiving amlodipine treatment compared to the control group (23). However, in the treatment of gestational hypertension, Yin et al. (24) found that amlodipine demonstrated superior efficacy to nifedipine, with reduced maternal side effect risks. Combination therapy with amlodipine has shown improved outcomes, such as significant blood pressure reduction and decreased incidence of peripheral edema when used with ACE inhibitors or diuretics (22, 25). Its combination with aliskiren exhibited enhanced antihypertensive effects without increasing adverse event rates (26). Valsartan not only largely prevents amlodipine-induced peripheral edema but also benefits cardiovascular morbidity and mortality, with protective effects on renal function (27). Nevertheless, peripheral edema remains an undeniable adverse effect of amlodipine, and our study found it to be independent of age and gender, suggesting that combination therapy should be considered clinically to reduce its incidence. At the genetic level, specific clinical studies have found that Chinese patients carrying CYP3A5 *3/*3 or CYP3A5 *1D/ *1D genotypes have a significantly increased risk of amlodipineinduced peripheral edema, while those with the CYP3A5 *1E genotype show a lower risk (28). Our study identifies peripheral

FI A

Ginaival Hypertrophy		223 048(150 612-330 321)
		223.040(130.012 330.321)
		217.000(75.920-025.105)
		62.976(42.061-94.247)
	-	50.454(35.763-71.180)
	-	36.120(26.006-50.168)
Intentional Overdose		19.277(16.652-22.315)
Hyperplasia	-	16.333(5.945-44.874)
Hyperdynamic Left Ventricle		14.63/(1.914-111.924)
Gingivitis		14.177(9.898-20.304)
Sinus Rhythm	a	12.976(4.034-41.743)
Gingival Pain		10.076(6.562-15.470)
Gingival Bleeding		10.074(7.460-13.604)
Suicide Attempt		8.587(7.100-10.385)
Obstructive Airways Disorder	•	7.569(5.554-10.316)
Orthostatic Hypotension		7.000(5.502-8.905)
Shock	•	6.860(5.397-8.720)
Haemodynamic Instability	•	6.662(4.164-10.659)
Blood Pressure Diastolic Decrea	ased	5.731(4.210-7.801)
Left Ventricular Hypertrophy	•	5.626(3.168-9.988)
Overdose	•	4.723(3.944-5.657)
Dyspnoea At Rest	•	4.553(2.431-8.526)
Hypotension	•	4.469(4.043-4.940)
Oedema Peripheral	•	4.382(3.854-4.982)
Bradycardia		4.224(3.566-5.005)
Completed Suicide	•	3.958(2.448-6.399)
Sinus Bradycardia	÷	2.541(1.551-4.163)
Metabolic Acidosis	•	2.417(1.753-3.332)
	100 000 100 500	
	100 200 300 400 500	
	Risk Factor	

edema as a noteworthy adverse reaction across all population groups, warranting further research to explore whether amlodipine-induced peripheral edema in American, European, and Asian populations is also associated with specific genotypes.

Drug-induced gingival overgrowth is a periodontal side effect of certain medications, believed to be associated with pathological growth of gingival tissue due to excessive expansion of the extracellular matrix, cell proliferation, and/or hypertrophy (29). It may be related to increased expression of IL-17A (30) and can lead to swelling, bleeding, and problems with chewing, aesthetics, and phonation, potentially resulting in tooth loss and deterioration of patients' quality of life (11). First reported in patients taking amlodipine in 1994 (31), it is now recognized as a major oral adverse reaction to the drug. Recent years have seen an increase in literature on amlodipine-induced gingival diseases, but these are mostly case reports and mechanism analyses, with few large-sample studies. Our study, based on real-world data from the FAERS database, not only confirmed gingival overgrowth but also identified rare gingival conditions including gingival swelling, gingivitis, gingival bleeding, and gingival pain. These conditions are interrelated, with one potentially triggering the simultaneous occurrence of others. Specifically, gingival hypertrophy and swelling are typically associated with inflammatory responses, which may lead to bleeding and pain. Research has emphasized that pre-existing periodontal inflammation may be a crucial factor in inducing hypertrophy (32), indicating a significant association between periodontal health status and drug-induced gingival overgrowth. Gingival inflammation is related to bacterial plaque accumulation forming microbial biofilms, and factors affecting the degree and severity of gingival swelling similarly exacerbate inflammatory responses caused by dental plaque (33). Although clinical studies report a prevalence of 3.4% for amlodipine-induced gingival overgrowth (34), our study found that associated adverse reactions are equally noteworthy, with gingival hypertrophy occurring at rates as high as 61.8%, possibly related to the upregulation of TGF-B1

and KGF gene expression (35). More significantly, in our study, gingival hypertrophy ranked highest in ROR across all five subgroup populations, suggesting that this adverse reaction requires broader clinical attention.

Shock is an acute circulatory failure state associated with infection, typically accompanied by hypotension and organ dysfunction (36). Distributive shock, a subtype, is characterized by pathological redistribution of the vascular system leading to relative hypovolemia, primarily related to vascular system dysfunction (37). It has been reported as a potential consequence of amlodipine overdose (38). In our study, distributive shock ranked among the top three adverse reactions by ROR score in all subgroups except the elderly, and may be complexly associated with other intersecting adverse reactions such as bradycardia, hypotension, left ventricular hypertrophy, and hemodynamic instability, potentially occurring simultaneously or exacerbating each other. Vasoplegia syndrome, a form of distributive shock characterized by low systemic vascular resistance including vasodilation and dysregulation of vascular smooth muscle cells (39), is commonly observed postcardiothoracic surgery. Our study identified it as a potential adverse reaction to amlodipine, consistent with a clinical case reported by L.A.A. (40). This ADR ranked among the top five by ROR score in all subgroups except the elderly. Notably, there is currently no comprehensive analysis of the association between amlodipine and the occurrence of distributive shock and vasoplegia syndrome, underscoring the importance of early recognition, prevention, and intervention for these conditions across all populations, particularly in younger individuals.

While upper respiratory tract infections are commonly reported adverse reactions when amlodipine is combined with other antihypertensive medications (41, 42), the FDA label indicates dyspnea as a respiratory system adverse effect, consistent with our finding of dyspnoea at rest. Watt et al. (43) reported that amlodipine use may lead to increased breathlessness during exercise, but our findings suggest that attention should also be paid to dyspnea occurrence at rest. Additionally, we identified obstructive airways disorder, indicating that dyspnea may be related to airflow limitation leading to airway obstruction, though specific mechanisms require further investigation.

Given that amlodipine users are predominantly elderly, with an average age of about 68.6 years (44), we identified a noteworthy adverse reaction in the elderly subgroup: BRASH syndrome. This recently recognized clinical entity is characterized by bradycardia, renal failure, AV node blockade, shock, and hyperkalemia. Its symptoms may overlap with other conditions, making it susceptible to oversight and misdiagnosis. BRASH syndrome has significant harmful effects, with a mortality rate of 5.7%, 20% of patients requiring renal replacement therapy, and up to 33% needing temporary pacing (45). It may progress to cardiogenic shock (46). Several case reports (46, 47–49) have documented BRASH syndrome in hypertensive patients taking amlodipine, aligning with our findings. While not a common adverse reaction across all subgroups in our study, its specific symptoms such as bradycardia, shock, and AV conduction block are among the 27 common adverse reactions we identified or related to them. BRASH syndrome ranked high among adverse reactions in the elderly subgroup, indicating its potential clinical risk. Regrettably, there is currently no literature specifically discussing the association between amlodipine use and the occurrence of BRASH syndrome, particularly in the elderly population, with most reports being case studies. Our study thus serves as an important warning about the significance of monitoring this emerging entity in elderly patients. BRASH syndrome represents a vicious cycle of hyperkalemia and bradycardia, and caution should be exercised when using amlodipine in high-risk populations, such as those with a history of hyperkalemia.

Furthermore, we identified some controversial ADRs, such as effects on cardiac rhythm and left ventricular structure. The FDA label lists both bradycardia and tachycardia as adverse reactions to amlodipine. Some studies have shown increased heart rate (50) and more specifically sinus tachycardia (51) after amlodipine use, possibly due to reflex tachycardia caused by reduced peripheral vascular resistance. However, specific clinical studies have reported that combined use of angiotensin axis antagonists with amlodipine may exacerbate adverse reactions such as hypotension and bradycardia (20). A cohort study using a fixeddose combination of bisoprolol and amlodipine also reported bradycardia as an adverse reaction (52). Although the individual effect of amlodipine was not evaluated in these studies, Ebihara et al. (53) reported a case of severe bradycardia in a patient taking a high dose of amlodipine, consistent with Mellor et al.'s (54) study suggesting that amlodipine may cause bradycardia by suppressing sympathetic nervous system activity. Combined with our results, we believe that amlodipine poses a risk of causing bradycardia and sinus bradycardia, and this risk is independent of age and gender.

Similarly, the adverse reaction of left ventricular hypertrophy is also controversial. Left ventricular hypertrophy is a change in cardiac structure and function that increases cardiac burden and may lead to serious complications such as heart failure and arrhythmias (55, 56). Amlodipine, due to its mechanism of action and its close relationship with the cardiovascular system, may lead to increased sympathetic activity, thereby affecting left ventricular structure (57). A clinical study based in Japan indicated that amlodipine can alleviate LV hypertrophy (58), and the same conclusion was drawn in hypertensive rats (59). However, an increasing body of literature has found that the effect of amlodipine in improving left ventricular hypertrophy is not as expected (60), showing its potential limitations in some hypertensive patients. A clinical study based on hypertensive populations showed that some patients using amlodipine longterm may experience morning hypertension, which is closely related to left ventricular hypertrophy (61). Takatsu et al. (62) also proposed that while amlodipine lowered blood pressure, it failed to effectively reverse indicators related to left ventricular hypertrophy, suggesting that amlodipine did not significantly improve left ventricular geometry and function. This is consistent with the study by Takeuchi et al. (63), which found that the use of amlodipine failed to effectively inhibit cardiomyocyte hypertrophy, especially in high-salt diet-induced models. Our study similarly found that amlodipine may exacerbate left ventricular hypertrophy, further emphasizing the complexity and limitations of this drug in clinical applications.

This study also identified some psychiatric ADRs, such as completed suicide, intentional overdose, and suicide attempt. We believe that suicide may be related to the decline in the patients' quality of life and increased financial burden caused by cardiovascular, oral gingival, and respiratory system diseases induced by amlodipine, which is consistent with reported cases (64). Suicide may occur through intentional overdose. Research has found that drug self-poisoning (DSP) is the most common suicide method globally, and amlodipine is ranked third among the most frequently reported drugs in this regard (65). Additionally, we identified some previously unreported ADRs, such as full blood count abnormal in the male population and personality disorder in the female population.

This study identified various ADRs associated with amlodipine, and since the FDA label has already noted most of them without in-depth discussion, such as myocardial depression, metabolic acidosis, orthostatic hypotension, and decreased diastolic blood pressure it underscores the reliability of our findings and indicates that many positive ADRs have not yet been emphasized. Drug safety is a crucial issue, and ADRs should be taken seriously. Although clinical observations and case reports make it difficult to assess whether potential ADRs associated with a drug are valid, and actual clinical observations may underestimate the prevalence of ADRs due to their low incidence rates, their potential ADRs should be thoroughly explored. As the first comprehensive investigation of the potential ADRs associated with the commonly used medication amlodipine, this study employed rigorous quality control measures, including retaining only reports where amlodipine was designated as the primary suspect and excluding reports submitted by nonhealthcare professionals. Furthermore, it integrated four positive signal detection methods and validated the findings through analyses and multivariable logistics regression. subgroup Consequently, this study provides compelling evidence that amlodipine poses risks of peripheral edema, shock, and dyspnea, among others, and identified previously unreported ADRs such as abnormal full blood count and personality disorder. These findings underscore the importance of exercising caution when prescribing amlodipine to high-risk individuals with a history of hyperkalemia, cardiac structural abnormalities, or airway obstruction.

This study inevitably has some limitations. First, while we have synthesized multiple streams of evidence to identify ADRs potentially linked to amlodipine use and have offered safety recommendations for clinical application, we are unable to establish definitive causal relationships. Second, the constraints and biases inherent in the sample sources limit the generalizability of our findings across diverse ethnic populations. Third, as the data were voluntarily reported, issues such as inconsistency in quality inevitably arise. Nevertheless, we have mitigated the impact on our study by including only reports submitted by healthcare professionals. Therefore, future research should strive to explore the underlying mechanisms in greater depth and incorporate more diverse and extensive samples to comprehensively evaluate the drug's effects across different ethnic groups.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

JJ: Formal analysis, Methodology, Software, Validation, Writing original draft, Writing - review & editing. QZ: Conceptualization, Formal analysis, Methodology, Software, Writing – original draft, Writing – review & editing. XZ: Formal analysis, Methodology, Writing – original draft. LZ: Data curation, Writing – review & editing, Visualization. JZ: Data curation, Validation, Writing – review & editing. BL: Data curation, Writing – review & editing, Validation. XD: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Correction Note

A correction has been made to this article. Details can be found at: 10.3389/fcvm.2025.1636315.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, et al. Treatment for beta-blocker poisoning: a systematic review. *Clin Toxicol* (*Phila*). (2020) 58(10):943–83. doi: 10.1080/15563650.2020.1752918

2. Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. (2022) 328(18):1849-61. doi: 10.1001/jama.2022.19590

3. Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. *J Geriatr Cardiol.* (2017) 14(1):67–72. doi: 10.11909/j. issn.1671-5411.2017.01.006

4. Wang JG, Palmer BF, Vogel AK, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens (Greenwich). (2023) 25(9):801–7. doi: 10.1111/jch.14709

5. Khurshid F, Aqil M, Alam MS, Kapur P, Pillai KK. Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teaching hospital in New Delhi. *Daru.* (2012) 20(1):34. doi: 10.1186/2008-2231-20-34

6. Zhang M, Li H, Huang L, Liu Y, Jiao XF, Zeng L, et al. Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system. *Eur J Pediatr.* (2023) 182(10):4655–61. doi: 10.1007/s00431-023-05146-2

7. Cvetković Z, Suvajdžić-Vuković N, Todorović Z, Panić M, Nešković A. Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review. J Clin Pharm Ther. (2013) 38(3):246–8. doi: 10.1111/jcpt.12051

8. Low L, Zaheri S, Wakelin S. Amlodipine-induced linear IgA disease. Clin Exp Dermatol. (2012) 37(6):649-51. doi: 10.1111/j.1365-2230.2011.04297.x

9. Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipineinduced toxic epidermal necrolysis. *J Burn Care Res.* (2011) 32(5):e158–60. doi: 10. 1097/BCR.0b013e31822ac7be

10. Murthy MB, Murthy B. Amlodipine-induced petechial rash. J Postgrad Med. (2011) 57(4):341–2. doi: 10.4103/0022-3859.90091

11. Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. *J Pharm Health Care Sci.* (2017) 3:19. doi: 10.1186/s40780-017-0088-5

12. Wang C, Zhu Q, Tan D, Walline J, Wang Y. Acute high-output heart failure with pulmonary hypertension and severe liver injury caused by amlodipine poisoning: a case report. *Cardiovasc Toxicol.* (2024) 24(5):513–8. doi: 10.1007/s12012-024-09849-2

13. Liu M, Luo D, Jiang J, Shao Y, Dai D, Hou Y, et al. Adverse tumor events induced by ranitidine: an analysis based on the FAERS database. *Expert Opin Drug Saf.* (2025) 24(1):35–47. doi: 10.1080/14740338.2024.2354325

14. Zheng B, Liu M, Dai D, Shang Y, Dou X, Liu B, et al. Safety of TNF- α inhibitors: a real-world study based on the US FDA adverse event reporting system database. *Medicine (Baltimore)*. (2024) 103(29):e39012. doi: 10.1097/MD.000000000039012

15. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. *Pharmacoepidemiol Drug Saf.* (2002) 11(1):3–10. doi: 10.1002/pds.668

16. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf.* (2001) 10(6):483-6. doi: 10.1002/pds.677

17. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. *Eur J Clin Pharmacol.* (1998) 54(4):315–21. doi: 10.1007/s002280050466

18. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. *Drug Saf.* (2002) 25(6):381–92. doi: 10.2165/00002018-200225060-00001

19. de Portu S, Mantovani LG. Amlodipine: a pharmacoeconomic review. J Med Econ. (2009) 12(1):60–8. doi: 10.3111/13696990802525266

20. Huang J, Buckley NA, Isoardi KZ, Chiew AL, Isbister GK, Cairns R, et al. Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning. *Clin Toxicol (Phila).* (2021) 59(6):464–71. doi: 10.1080/15563650.2020.1826504

21. Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Boehm M, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. *J Hypertens*. (2019) 37(10):2093–103. doi: 10. 1097/HJH.00000000002145

22. Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis. *J Clin Hypertens (Greenwich)*. (2022) 24(5):536–54. doi: 10.1111/jch.14436

23. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). *JACC Heart Fail.* (2013) 1(4):308–14. doi: 10.1016/j.jchf.2013.04.004

24. Yin J, Mei Z, Shi S, Du P, Qin S. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet. (2022) 306(6):1891–900. doi: 10.1007/s00404-022-06504-5

25. Elliott WJ, Bistrika EA. Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. *Expert Opin Drug Saf.* (2018) 17(2):207–16. doi: 10.1080/14740338.2018.1397129

26. Liu Y, Chen K, Kou X, Liu Y, Chen K, Kou X, et al. Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. *PLoS One.* (2013) 8(7):e70111. doi: 10.1371/journal.pone.0070111

27. Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. *Vasc Health Risk Manag.* (2009) 5(1):165–74. doi: 10.2147/vhrm.s3134

28. Liang H, Zhang X, Ma Z, Sun Y, Shu C, Zhu Y, et al. Association of CYP3A5 gene polymorphisms and amlodipine-induced peripheral edema in Chinese han patients with essential hypertension. *Pharmgenomics Pers Med.* (2021) 14:189–97. doi: 10.2147/PGPM.S291277

29. Droździk A, Droździk M. Drug-induced gingival overgrowth-molecular aspects of drug actions. Int J Mol Sci. (2023) 24(6):5448. doi: 10.3390/ijms24065448

30. Sume SS, Berker E, Ilarslan Y, Ozer Yucel O, Tan C, Goyushov S, et al. Elevated interleukin-17A expression in amlodipine-induced gingival overgrowth. *J Periodontal Res.* (2020) 55(5):613–21. doi: 10.1111/jre.12747

31. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. *J Clin Periodontol.* (1994) 21(4):281–3. doi: 10.1111/j.1600-051x. 1994.tb00318.x

32. Nanda T, Singh B, Sharma P, Arora KS. Cyclosporine A and amlodipine induced gingival overgrowth in a kidney transplant recipient: case presentation with literature review. *BMJ Case Rep.* (2019) 12(5)e229587. doi: 10.1136/bcr-2019-229587

33. Murakami S, Mealey BL, Mariotti A, Chapple IL. Dental plaque-induced gingival conditions. J Periodontol. (2018) 89(Suppl 1):S17–27. doi: 10.1002/JPER.17-0095

34. Damdoum M, Varma SR, Nambiar M, Venugopal A. Calcium channel blockers induced gingival overgrowth: a comprehensive review from a dental perspective. *J Int Soc Prev Community Dent.* (2022) 12(3):309–22. doi: 10.4103/jispcd.JISPCD_57_22

35. Mojsilović J, Jovičić N, Vujović RS, Stevanović M, Mijailović S, Rosić G, et al. Novel insights into amlodipine-induced gingival enlargement: a clinical and molecular perspective. *Pharmaceuticals (Basel)*. (2024) 17(8):1075. doi: 10.3390/ph17081075

36. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA*. (2016) 315(8):775–87. doi: 10.1001/jama.2016.0289

37. Standl T, Annecke T, Cascorbi I, Heller AR, Sabashnikov A, Teske W. The nomenclature, definition and distinction of types of shock. *Dtsch Arztebl Int.* (2018) 115(45):757–68. doi: 10.3238/arztebl.2018.0757

38. Yusuke M, Hidetoshi Y, Yusuke T, Koji I, Masahito T, Susumu Y, et al. Intoxication with massive doses of amlodipine and candesartan requiring venoarterial extracorporeal membrane oxygenation. *Acute Med Surg.* (2023) 10(1): e878. doi: 10.1002/ams2.878

39. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. *Crit Care.* (2020) 24(1):36. doi: 10.1186/s13054-020-2743-8

40. Ayasa LA, Azar J, Odeh A, Ayyad M, Shbaita S, Zidan T, et al. Hydroxocobalamin as rescue therapy in a patient with refractory amlodipine-induced vasoplegia. *Cureus.* (2023) 15(5):e38400. doi: 10.7759/cureus.38400

41. Hu D, Liu L, Li W. Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study. Adv Ther. (2014) 31(7):762–75. doi: 10.1007/s12325-014-0132-x

42. Littlejohn TR, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. *Curr Med Res Opin*. (2009) 25(4):951–9. doi: 10.1185/03007990902785845

43. Watt M, Peacock AJ, Newell J, McDonagh T, Grant S. The effect of amlodipine on respiratory and pulmonary vascular responses to hypoxia in mountaineers. *Eur Respir J.* (2000) 15(3):459–63. doi: 10.1034/j.1399-3003.2000.15.06.x

44. Volpe M, Pegoraro V, Heiman F, Cipelli R. Extemporaneous combination therapy with amlodipine/zofenopril in hypertensive patients: a real-world data analysis in Italy. *Curr Med Res Opin.* (2023) 39(12):1593–601. doi: 10.1080/03007995.2023.2192607

45. Majeed H, Khan U, Khan AM, Khalid SN, Farook S, Gangu K, et al. BRASH syndrome: a systematic review of reported cases. *Curr Probl Cardiol.* (2023) 48(6):101663. doi: 10.1016/j.cpcardiol.2023.101663

46. Lai PC, Weng TI, Yu JH. BRASH syndrome progressing rapidly to cardiogenic shock: a case with confirmed excessive amlodipine concentration. *CJEM*. (2024) 26(4):280–2. doi: 10.1007/s43678-024-00651-1

47. Lei M, Cao Y, Yuan M, Xiong J, He H. Case report: a case of bradycardia triggered by diarrhea. *Front Med (Lausanne).* (2024) 11:1405494. doi: 10.3389/fmed. 2024.1405494

48. Ng CT, Lim KX, Loo KN. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia (BRASH) syndrome: a rising entity of severe bradycardia. *Cureus.* (2023) 15(2):e35620. doi: 10.7759/cureus.35620

49. Gouveia R, Veiga H, Costa AA, Pereira J, Lourenço P. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia syndrome due to amlodipine: a case report of an underdiagnosed medical condition. *Cureus.* (2022) 14(1):e21144. doi: 10.7759/cureus.21144

50. Silke B, Frais MA, Midtbo KA, Verma SP, Sharma S, Reynolds G, et al. Comparative hemodynamic dose-response effects of five slow calcium channelblocking agents in coronary artery disease. *Clin Pharmacol Ther.* (1987) 42(4):381–7. doi: 10.1038/clpt.1987.167

51. Stanek EJ, Nelson CE, DeNofrio D. Amlodipine overdose. Ann Pharmacother. (1997) 31(7-8):853-6. doi: 10.1177/106002809703100708

52. Hostalek U, Czarnecka D, Koch EM. Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients. *Cardiol Ther.* (2015) 4(2):179–90. doi: 10.1007/s40119-015-0045-z

53. Ebihara T, Morita M, Kawada M, Amano K, Kato F, Nakata Y. Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia. *Acute Med Surg.* (2017) 4(3):353–7. doi: 10.1002/ams2.284

54. Mellor K, Khan N, Iatan I, Tran K. PS-BPR02-6: not for the faint of heart: a case report of bradycardia induced hypertension. *J Hypertens*. (2023) 41(Suppl 1):e350. doi: 10.1097/01.hjh.0000916328.81781.88

55. Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association. *Cardiovasc Res.* (2023) 119(11):2017–32. doi: 10.1093/cvr/cvad083

56. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. *JACC Heart Fail*. (2017) 5(8):543–51. doi: 10.1016/j.jchf. 2017.04.012

57. J-ELAN Investigators. Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. *Circ J.* (2006) 70(1):124–8. doi: 10.1253/circj.70.124

58. Yamamoto K, Ozaki H, Takayasu K, Akehi N, Fukui S, Sakai A, et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. *Hypertens Res.* (2011) 34(3):325–30. doi: 10.1038/hr.2010.237

59. Sevilla MA, Voces F, Carrón R, Guerrero EI, Ardanaz N, San Román L, et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. *Life Sci.* (2004) 75(7):881–91. doi: 10.1016/j.lfs.2004.04.004

60. Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. *Am J Cardiol.* (2009) 104(3):359–65. doi: 10.1016/j.amjcard.2009.03.042

61. Ikeda T, Gomi T, Shibuya Y, Shinozaki S, Suzuki Y, Matsuda N. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. *Hypertens Res.* (2007) 30(11):1097–105. doi: 10.1291/ hypres.30.1097

62. Takatsu M, Hattori T, Murase T, Ohtake M, Kato M, Nashima K, et al. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. *J Hypertens*. (2012) 30(9):1845–55. doi: 10.1097/HJH.0b013e3283567645

63. Takeuchi F, Liang YQ, Isono M, Ang MY, Mori K, Kato N. Transcriptomic response in the heart and kidney to different types of antihypertensive drug administration. *Hypertension*. (2022) 79(2):413–23. doi: 10.1161/HYPERTENSIONAHA.121.18026

64. Santunione AL, Palazzoli F, Verri P, Vandelli D, Castagnetti V, Profeta C, et al. Cardiovascular drugs and suicide death: determination of carvedilol, amlodipine, doxazosin and diltiazem in two fatal cases. *J Pharm Biomed Anal.* (2024) 238:115831. doi: 10.1016/j.jpba.2023.115831

65. Fusaroli M, Pelletti G, Giunchi V, Pugliese C, Bartolucci M, Necibi EN, et al. Deliberate self-poisoning: real-time characterization of suicidal habits and toxidromes in the food and drug administration adverse event reporting system. *Drug Saf.* (2023) 46(3):283–95. doi: 10.1007/s40264-022-01269-x